Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

• Yasuhiro Oki,
• Anas Younes,
• Javier Knickerbocker,
• Felipe Samaniego,
• Loretta Nastoupil,
• Fredrick Hagemeister,
• Jorge Romaguera,
• Nathan Fowler,
• Larry Kwak,
• Jason Westin

Affiliations

Yasuhiro Oki

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA

Anas Younes

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA

Javier Knickerbocker

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA

Felipe Samaniego

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA

Loretta Nastoupil

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA

Fredrick Hagemeister

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA

Jorge Romaguera

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA

Nathan Fowler

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA

Larry Kwak

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA

Jason Westin

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA